BMRN – biomarin pharmaceutical inc. (US:NASDAQ)

DELAYED
$ usd
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
1D
5D
1M
3M
YTD
1Y
3Y
1 Day BMRN SPY QQQ SPX
Date
Time
Symbol
Company Name
Action
%Chg
10/27/2025
04:03 pm
bmrn
biomarin pharmaceutical inc.
MISS
1.6%
8/4/2025
04:02 pm
bmrn
biomarin pharmaceutical inc.
BEAT
2.7%
5/1/2025
04:05 pm
bmrn
biomarin pharmaceutical inc.
BEAT
-1.1%
2/19/2025
04:05 pm
bmrn
biomarin pharmaceutical inc.
BEAT
5.3%
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions?
The answers are right here.
Stock Stats
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Top News Gainers
5/14 Form 4 BIOMARIN PHARMACEUTICAL For: May 10 Filed by: BIENAIME JEAN JACQUES 7.5%
2/20 BioMarin's Biologics License Application for Valoctocogene Roxaparvovec Accepted for Priority Review by FDA with Review Action Date of August 21, 2020 6.0%
3/24 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "outperform" rating re-affirmed by analysts at Wedbush. 5.4%
3/3 Coronavirus Correction Watchlist: 11 More Stocks [Investor's Business Daily] 5.0%
4/9 Form 4 BIOMARIN PHARMACEUTICAL For: Apr 08 Filed by: Ajer Jeffrey Robert 4.3%
12/14 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Robert W. Baird. They now have a $120.00 price target on the stock. 4.2%
7/9 BioMarin Appoints Pharmaceutical Veteran and Former J & J Executive, Liz McKee Anderson, to Board of Directors 3.4%
4/13 Form 4 BIOMARIN PHARMACEUTICAL For: Apr 09 Filed by: BIENAIME JEAN JACQUES 3.3%
3/1 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $164.00 price target on the stock. 3.2%
12/12 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Bank of America Corp. They now have a $90.00 price target on the stock. 2.9%
Top News Decliners
3/11 Form 4 BIOMARIN PHARMACEUTICAL For: Mar 03 Filed by: BIENAIME JEAN JACQUES -12.3%
5/28 BioMarin Announces that Phase 3 Cohort of Valoctocogene Roxaparvovec, Gene Therapy Study in Severe Hemophilia A Met Pre-Specified Criteria for Regulatory Submissions in the U.S. and Europe -7.9%
4/6 BioMarin Plans Regulatory Submissions for Marketing Authorization of Vosoritide to Treat Children with Achondroplasia in 3Q 2020 in both US and Europe -5.4%
4/15 Biomarin Could Possibly Be The First To Obtain FDA Approval For Hemophilia Gene Therapy Treatment [Seeking Alpha] -5.3%
3/17 Form 4 BIOMARIN PHARMACEUTICAL For: Mar 13 Filed by: BAFFI ROBERT -4.8%
4/30 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -4.2%
3/16 Why BioMarin Pharmaceutical, Bristol-Myers Squibb, and bluebird bio Are Getting Hammered Monday [The Motley Fool] -4.1%
1/11 These 3 Biotech Stocks Could Be Top Stocks in 2020 [The Motley Fool] -4.1%
10/1 BioMarin to Participate in Jefferies Gene Therapy/Editing Summit on October 8, 2019 in New York -3.9%
5/1 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. They now have a $108.00 price target on the stock. -3.9%

Don’t Miss Out On The Next BIG Stock Move

Thanks for submitting the form.
BMRN – biomarin pharmaceutical inc. (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
BMRN
SPY
QQQ
SPX
BMRN – biomarin pharmaceutical inc. (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
BMRN SPY QQQ SPX
Stock Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Stock Stats
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
News
2/11
01:01 pm
bmrn
Low
Pharma companies left out of Trump's drug-pricing deals look for way in [Yahoo! Finance Canada]
2/6
10:58 am
bmrn
Low
BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target lowered by analysts at Piper Sandler from $122.00 to $84.00. They now have an "overweight" rating on the stock.
2/2
09:40 am
bmrn
Low
Jefferies Downgrades Amicus Therapeutics, Inc. (FOLD) to Buy And Lowers Price Target Amid Takeover Developments [Yahoo! Finance]
1/31
07:03 pm
bmrn
Low
Should You Buy BioMarin Pharmaceutical Before Feb. 18? [Yahoo! Finance]
1/29
04:05 pm
bmrn
Low
BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility
1/29
01:55 am
bmrn
Low
BioMarin's Amicus Deal Funding Reshapes Debt Load And Rare Disease Reach [Yahoo! Finance]
1/28
08:03 am
bmrn
Low
BioMarin Pharmaceutical (NASDAQ:BMRN) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $80.00 price target on the stock.
1/28
07:13 am
bmrn
Low
Upcoming Acquisition Resulting in Bullish Stance on BioMarin Pharmaceutical (BMRN) [Yahoo! Finance]
1/26
08:02 am
bmrn
Medium
BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility [Yahoo! Finance]
10/27/2025
04:03 pm
bmrn
1.6%
MISS
8/4/2025
04:02 pm
bmrn
2.7%
BEAT
5/1/2025
04:05 pm
bmrn
-1.1%
BEAT
2/19/2025
04:05 pm
bmrn
5.3%
BEAT
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions? The answers are right here.
1/28
08:03 am
Initiates
Overweight
Barclays PLC
Low
-1.7%
1/20
07:55 am
Upgrades
Hold
Buy
Canaccord Genuity
Medium
3.2%
1/20
05:05 am
Upgrades
HOLD
BUY
CANACCORD
Low
2.4%
12/3
08:42 am
Reiterates
Outperform
Market Perform
Leerink Partners
Low
1.6%
12/3
08:34 am
Downgrades
Outperform
Market Perform
Leerink Partners
Low
1.6%
12/3
06:31 am
Downgrades
OUTPERFORM
MARKET PERFORM
LEERINK
Low
0.6%
12/3
06:10 am
Downgrades
OUTPERFORM
MARKET PERFORM
LEERINK
Low
0.8%
1/29
04:20 pm
bmrn
Low
Form 8-K BIOMARIN PHARMACEUTICAL For: Jan 29
1/26
07:55 am
bmrn
Medium
Form 8-K BIOMARIN PHARMACEUTICAL For: Jan 26
1/22
06:12 pm
bmrn
Low
Form 4 BIOMARIN PHARMACEUTICAL For: Jan 20 Filed by: Ramchandani Rashmi Virendra
1/22
06:09 pm
bmrn
Low
Form 3 BIOMARIN PHARMACEUTICAL For: Jan 20 Filed by: Ramchandani Rashmi Virendra
1/21
12:31 pm
bmrn
Low
Form SCHEDULE 13G/A BIOMARIN PHARMACEUTICAL Filed by: BlackRock, Inc.
1/12
04:45 pm
bmrn
Medium
Form 8-K BIOMARIN PHARMACEUTICAL For: Jan 12
12/22
09:00 am
bmrn
Low
Form 8-K BIOMARIN PHARMACEUTICAL For: Dec 19
12/19
08:47 am
bmrn
High
Form 8-K BIOMARIN PHARMACEUTICAL For: Dec 19
12/17
04:07 pm
bmrn
Low
Form 8-K BIOMARIN PHARMACEUTICAL For: Dec 11
Show more
Top News Gainers
5/14 Form 4 BIOMARIN PHARMACEUTICAL For: May 10 Filed by: BIENAIME JEAN JACQUES 7.5%
2/20 BioMarin's Biologics License Application for Valoctocogene Roxaparvovec Accepted for Priority Review by FDA with Review Action Date of August 21, 2020 6.0%
3/24 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "outperform" rating re-affirmed by analysts at Wedbush. 5.4%
3/3 Coronavirus Correction Watchlist: 11 More Stocks [Investor's Business Daily] 5.0%
4/9 Form 4 BIOMARIN PHARMACEUTICAL For: Apr 08 Filed by: Ajer Jeffrey Robert 4.3%
12/14 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Robert W. Baird. They now have a $120.00 price target on the stock. 4.2%
7/9 BioMarin Appoints Pharmaceutical Veteran and Former J & J Executive, Liz McKee Anderson, to Board of Directors 3.4%
4/13 Form 4 BIOMARIN PHARMACEUTICAL For: Apr 09 Filed by: BIENAIME JEAN JACQUES 3.3%
3/1 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $164.00 price target on the stock. 3.2%
12/12 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Bank of America Corp. They now have a $90.00 price target on the stock. 2.9%
Top News Decliners
3/11 Form 4 BIOMARIN PHARMACEUTICAL For: Mar 03 Filed by: BIENAIME JEAN JACQUES -12.3%
5/28 BioMarin Announces that Phase 3 Cohort of Valoctocogene Roxaparvovec, Gene Therapy Study in Severe Hemophilia A Met Pre-Specified Criteria for Regulatory Submissions in the U.S. and Europe -7.9%
4/6 BioMarin Plans Regulatory Submissions for Marketing Authorization of Vosoritide to Treat Children with Achondroplasia in 3Q 2020 in both US and Europe -5.4%
4/15 Biomarin Could Possibly Be The First To Obtain FDA Approval For Hemophilia Gene Therapy Treatment [Seeking Alpha] -5.3%
3/17 Form 4 BIOMARIN PHARMACEUTICAL For: Mar 13 Filed by: BAFFI ROBERT -4.8%
4/30 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -4.2%
3/16 Why BioMarin Pharmaceutical, Bristol-Myers Squibb, and bluebird bio Are Getting Hammered Monday [The Motley Fool] -4.1%
1/11 These 3 Biotech Stocks Could Be Top Stocks in 2020 [The Motley Fool] -4.1%
10/1 BioMarin to Participate in Jefferies Gene Therapy/Editing Summit on October 8, 2019 in New York -3.9%
5/1 BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. They now have a $108.00 price target on the stock. -3.9%